Background. The rate of decline in kidney function is a powerful predictor of cardiovascular risk in patients with chronic kidney disease (CKD). Serum phosphate and increased arterial stiffness are associated with elevated cardiovascular risk in CKD and the general population. We sought to determine whether serum phosphate and markers of arterial stiffness predict progression of renal dysfunction in patients with early CKD. Methods. Two hundred and twenty-five patients with Stage II-IV CKD were prospectively followed up at University Hospital Birmingham. Serum phosphate was measured at baseline and arterial stiffness was determined through measurement of aortic pulse wave velocity (PWV) and augmentation index (AIx). Progression of renal dysfunction was defined as the slope of estimated glomerular filtration rate (eGFR) against time. We determined the associations between possible predictors and rate of progression and also examined a combined end point of start of dialysis or !25% decline in eGFR. Results. Mean baseline eGFR was 43 6 19 mL/min/1.73 m 2 and serum phosphate 1.22 6 0.27 mmol/L. Median followup was 924 days. Serum phosphate independently predicted a greater decline in eGFR; a 1 mmol/L increment in serum phosphate was associated with a 0.34 mL/min/month steeper decline (P ¼ 0.02). Brachial and aortic systolic pressure independently predicted the rate of renal function decline but aortic PWV and AIx had no significant influence. Forty-one patients (18%) reached the combined end point; serum phosphate was significantly higher in this group (1.32 6 0.36 versus 1.19 6 0.24 mmol/L, P ¼ 0.04) and was an independent predictor for the combined end point. Conclusions. Serum phosphate independently predicts decline in renal function in early CKD. Further studies are required to determine the mechanisms involved and to investigate the potential benefits of phosphate lowering on preserving kidney function.
Introduction
Patients with chronic kidney disease (CKD) have high levels of cardiovascular morbidity and mortality with an inverse relationship to glomerular filtration rate (GFR) [1] . Classical cardiovascular risk factors such as obesity, hyperlipidaemia, diabetes, hypertension and tobacco use do not fully explain this increased risk, indicating that other factors contribute to this adverse cardiovascular prognosis [2] . One 'alternative' risk factor for future cardiovascular morbidity and mortality is the rate of deterioration in renal function with some studies suggesting it is a better predictor than baseline renal function [3, 4] . Markers of decline in renal function may therefore prove to be reliable determinants of future cardiovascular risk in this population.
Disorders of mineral-bone metabolism, particularly elevated serum phosphate, are emerging as powerful cardiovascular risk factors in the general population and in CKD, most dramatically in patients on dialysis [5] [6] [7] [8] . Phosphate predicts progression of renal dysfunction in 'advanced' (Stage IV and V) CKD [9] , in hypertensive renal disease in African-Americans [10] and, more recently, in transplant recipients [11, 12] . Similarly, markers of arterial stiffness such as pulse wave velocity (PWV) and augmentation index (AIx) predict cardiovascular mortality and morbidity in dialysis and hypertensive patients as well as in patients with coronary artery disease [13] . We have therefore investigated the impact of serum phosphate levels, simultaneously with PWV and AIx, on progression of renal dysfunction in a well characterized cohort of patients with 'early' CKD recruited from a University hospital.
Materials and methods

Study overview
This was a prospective, observational single-centre cohort study. Approval for the study was obtained from the South Birmingham Research Ethics Committee and written informed consent obtained from each participant. The study was conducted in accordance with the 'Declaration of Helsinki' and the principles of 'Good Clinical Practice'.
Participants
Subjects were recruited from specialist renal clinics at Queen Elizabeth Hospital, Birmingham from May 2004 to October 2007. Inclusion criteria were CKD as defined by Kidney Dialysis Outcomes Quality Initiative (K/DOQI) [14] not yet on dialysis, stable renal function within the last 3 months (<5 mL/min/1.73 m 2 change) and no change in medication in the preceding 3 months. Patients with atrial fibrillation, known left ventricular dysfunction (ejection fraction <55%) or with signs and symptoms of congestive heart failure were excluded. Patients on calcineurin inhibitors were excluded because of the known direct haemodynamic effects of these agents. Patients on phosphate binders and vitamin D analogues were also excluded.
Outcome measures
Follow-up data were prospectively collected. At outpatient review venous blood was routinely collected and analyzed for phosphate, calcium, parathyroid hormone (PTH) and other haematological and biochemical parameters. Serum calcium levels were corrected for albumin level. All serum creatinine values were measured during normal clinical practice and recorded for the duration of follow-up. GFR was estimated (eGFR) by the 4-variable Modification of Diet in Renal Disease formula with serum creatinine recalibrated to be traceable to an isotope derived mass spectroscopy method [15] . Progression of renal dysfunction was defined as the slope of eGFR plotted against time. Time was defined as time between data collection until death, start of renal replacement therapy or study termination. A combined end point of start of dialysis (excluding temporary dialysis) or !25% decline in eGFR since study entry was used. The study database was closed in September 2008. Follow-up data were censored at the start of renal replacement therapy or death.
Brachial artery pressure was measured in triplicate using validated oscillometric techniques (HEM-705CP; Omron [16] or Dinamap Procare 200; GE) [17] according to British Hypertension Society guidelines [18] . Aortic PWV was measured using the SphygmoCor device (AtCor Medical, Sydney, Australia) by sequentially recording ECG-gated carotid and femoral artery waveforms using a high-fidelity micromanometer (SPC-301; Millar Instruments, Houston, TX) as previously described [13] . Central pressure waveforms were derived and analyzed using pulse wave analysis as previously described [19] [20] [21] . In brief, the micromanometer was used to flatten, but not occlude, the radial artery. Data were collected directly into a computer to generate a peripheral waveform and corresponding central waveform. The central waveform was then analyzed to determine AIx and central aortic pressures. AIx represents the difference between the second and first peaks of the central pressure waveform in systole, expressed as a percentage of the pulse pressure. Given the known effects of heart rate AIx was corrected to a heart rate of 75 beats per minute (AIx 75 ) [22] . All values were measured in triplicate and averaged. Both methods are reproducible in healthy subjects and patients with CKD [19] [20] [21] 23] .
Statistical analysis
All data were analyzed using SPSS version 16 (SPSS Inc, Chicago, IL). Data distribution was tested using the Kolmogorov-Smirnov test. Nonnormally distributed data were log-transformed before analysis. Data are shown as mean AE standard deviation or as median (interquartile range) as appropriate. Between-groups comparisons were made by Student's t-test. Aortic PWV is partly blood pressure (BP) dependent so values were adjusted for mean arterial pressure [24] . Adjustment was performed by a linear regression of the two variables; residual values were then added to the mean aortic PWV. These values are presented as PWV adj . Linear and logistic regression analysis was used to assess the relationship between decline in renal function and parameters under investigation. In multivariate analyses, variables associated with decline in kidney function as defined by K/DOQI were used, including baseline eGFR, haemoglobin and systolic BP [14] . Analysis was also corrected for age, gender and proteinuria [14, 25, 26] . Co-linearity between explanatory variables was assessed by examining the variance inflation factor. A Type I error rate below 5% (P < 0.05) was considered statistically significant. Receiver operated characteristic (ROC) curves were used to compare the ability of calcium, phosphate and PTH to discriminate between patients who were in the top quartile for renal function decline and those that were not. Scores derived from a multiple logistic regression model incorporating age, gender, serum calcium, haemoglobin, systolic BP, baseline eGFR and logtransformed urine albumin: creatinine ratio were used to create ROC curves with phosphate, AIx and PWV individually added to compare their ability to discriminate between patients who were in the top quartile for renal function decline and those that were not. Non-parametric methods were used to compare the area under the curves (AUCs) and the results reported as AUC with 95% confidence intervals (CIs).
Results
In total, 257 patients were recruited. Thirty-two patients were excluded due to incomplete data collection leaving 225 subjects used in analyses. Demographic, biochemical and co-morbidity characteristics of these patients are listed in Table 1 . Renal diagnoses and medication at recruitment are listed in Table 2 . Patients were on average on 2.0 AE 1.2 antihypertensive agents. Median follow-up was 924 days (interquartile range 637-1176) and the median number of eGFR determinations per patient was 10 (7-14). 11 (5%) patients died during follow-up.
Baseline
The mean baseline eGFR was 43 AE 19 mL/min/1.73 m 2 ( Serum phosphate levels were significantly inversely associated with baseline eGFR (b ¼ À0.19, P ¼ 0.005). After correction for baseline eGFR, serum phosphate was associated with PTH (b ¼ 0.28, P < 0.0001), higher albuminuria (b ¼ 0.14, P ¼ 0.04), lower haemoglobin (b ¼ 0.18, P ¼ 0.008), lower calcium (b ¼ 0.14, P ¼ 0.048) and female gender (b ¼ 0.19, P ¼ 0.005).
Decline in renal function
The mean decline in renal function was 0.11 AE 0.54 mL/ min/month. Serum phosphate was significantly associated with decline in renal function ( Figure 1 , Table 3 ): a 1 mmol/L increase in serum phosphate was associated with a 0.34 mL/min/month steeper slope of renal function decline (P ¼ 0.01). After adjusting for risk factors known to accelerate progression of renal dysfunction (baseline eGFR, haemoglobin, systolic BP, age, gender and proteinuria), serum phosphate remained independently associated with the rate of decline (P ¼ 0.02; Table 3 ). Omission of haemoglobin from the model or inclusion of renal diagnosis or medication made no appreciable difference to the result. Further adjustment for albumin did not influence the rate of decline in renal function at 0.343 (0.064-0.623) mL/min/month. When dichotomized on cut-off points defined in the KDIGO guidelines [27] , patients with a plasma phosphate concentration >1.2 mmol/L had a 0.147 (0.000-0.304; P ¼ 0.05) mL/min/month steeper decline than patients with levels below this cut-off point.
Serum calcium was not significantly associated with kidney function decline over the follow-up period (P ¼ 0.2). In the subgroup of 200 patients with PTH results, higher PTH was associated with a slightly greater decline in renal function [0.002 (0.001-0.002) mL/min/month; P < 0.0001]. For prediction of a patient in the quartile with the highest rate of renal function decline, the AUC was greater for phosphate (0.61; 95% CI 0.51-0.70; P ¼ 0.03) than for calcium or PTH, neither of which was significantly >0.5.
Brachial and aortic systolic BP were associated with decline in renal function; each 1 mmHg higher systolic pressure was associated with a 0.005 and 0.006 mL/min/month steeper slope of renal function decline, respectively, (P ¼ 0.01 and P ¼ 0.004). After adjustment for risk factors known to accelerate renal decline, higher brachial and aortic systolic pressure remained independently associated with more rapid rates of decline [0.005 (0.000-0.009) and 0.006 (0.002-0.01) mL/min/month (P ¼ 0.020 and 0.008), respectively, Table 3 ]. Neither PWV nor AIx 75 were associated with the rate of renal function decline whether unadjusted or adjusted for known risk factors (Table 3) . These results were not influenced by either adjusting for brachial mean arterial pressure or aortic systolic or mean arterial pressure. For prediction of a patient being in the highest quartile of renal function decline the AUC for a ROC curve derived from a multiple logistic regression score incorporating age, gender, serum calcium, haemoglobin, systolic BP, baseline eGFR and log transformed urine albumin: creatinine ratio was 0.68 (95% CI 0.58-0.77; P < 0.001). Addition of AIx (0.66; 95% CI 0.57-0.76; P < 0.001) or PWV (0.67; 95% CI 0.58-0.77; P < 0.001) did not increase the AUC. The addition of phosphate to the model increased the AUC to 0.77 (95% CI 0.61-0.79; P < 0.001).
Combined renal end point
Comparison of characteristics of participants who did and did not reach the combined end point of commencement of dialysis or !25% decline in eGFR is shown in Table 4 . Consistent with the results of eGFR slope, there was a significant difference in serum phosphate and brachial and aortic pressures but no differences in AIx 75 or PWV between the two groups. Serum phosphate was independently associated with the combined end point (Beta 0.211, P ¼ 0.03) after adjustment for age, gender, baseline eGFR, systolic BP, proteinuria, haemoglobin and serum calcium. Neither AIx, PWV nor PWV adj were associated with the combined end point (Beta 0.5, P ¼ 0.1; À0.02, P ¼ 0.2; 0.02, P ¼ 0.1) after adjustment.
Discussion
In this observational study of 225 patients with predominantly early CKD, we have demonstrated that baseline serum phosphate predicts progression of renal dysfunction over a median follow-up of 2½ years. This association persisted following adjustment for factors known to accelerate renal function decline including age, proteinuria and systolic BP. Brachial and aortic systolic BP also independently predicted a decline in renal function, although no association was found with measures of arterial stiffness. These findings were supported by the presence of a significantly higher phosphate concentration in those patients reaching the combined renal end point of dialysis or !25% decline in eGFR compared to those that did not.
Serum phosphate as a predictor of declining renal function
Serum phosphate has been shown to predict decline in renal function in patients with advanced (Stages IV and V) CKD [9] . In our study of patients with predominantly early CKD, we have observed an equivalent change in slope of renal function per equivalent increase in serum phosphate concentration as observed in the study of advanced CKD (0.11 mL/min/month versus 0.15 mL/min/month decline per 1 mg/dL increase in serum phosphate; a 1 mg/dL change in serum phosphate is equivalent to 0.32 mmol/L change). Similarly, in a community study of AfricanAmericans with hypertensive renal disease and eGFR ranging from 20-65 mL/min/1.73 m 2 serum phosphate was independently associated with an increased risk of decline in eGFR (by 50% or 25 mL/min/1.73 m 2 ) or progression to end-stage kidney disease (ESKD) [10] . Serum phosphate was also an independent predictor of CKD progression in a cohort study of 985 males with Stage I-V CKD [28] . A 1 mg/dL increase in serum phosphate was associated with an adjusted hazard ratio of 1.29 of the composite end point of ESKD or doubling of serum creatinine, although only the highest quartile of serum phosphate showed a significant hazard ratio for the composite end point; this quartile comprised subjects with predominantly Stage IV CKD. Our results confirm that phosphate predicts rate of decline in renal function across a broad range of patients with widely varying severity and aetiology of CKD. The mechanism underlying the association between serum phosphate and progression of renal dysfunction is unknown. The Western diet is typically rich in bioavailable phosphate, resulting in high renal phosphate load [29] . A study of variable dietary phosphate content in uraemic rat models in the 1980s provided interesting insights into potential mechanisms of kidney damage [30] . Higher dietary phosphate was associated with greater urinary phosphate excretion and greater calcium and phosphate deposition in the renal tubules and interstitium of subtotally nephrectomized rats. Interstitial oedema and fibrosis, together with tubular atrophy and dilatation, were present histologically. The nephrotoxicity of phosphate appeared to increase as renal functional mass decreased. It has been hypothesized that high intracellular phosphate promotes precipitation of calcium-phosphate product within renal tubules or that phosphate itself acts as a direct tubular toxin [31] . Dietary restriction of phosphate in animal models has been shown to reduce progression of kidney disease [32] and use of the non-calcium-based phosphate binder sevelamer hydrochloride reduces renal calcium content and appears to protect against further deterioration in renal function [33, 34] .
Serum phosphate has also been established as a predictor of cardiovascular mortality in the general population and in CKD, including renal transplant and dialysis patients [7, 11, 35, 36] . We have speculated that much of this cardiovascular risk might be attributed to direct effects of phosphate on the vasculature and myocardium [29] , but considering the strong relationships between renal function and rate of decline in renal function and cardiovascular risk, it is also possible that phosphate might exert its effects on cardiovascular risk indirectly via the kidney.
Markers of arterial stiffness and renal function decline
Brachial and aortic systolic BP both independently predicted progression of kidney disease in our cohort, despite brachial BP being controlled to national targets (mean 138/ 80 mmHg). This has been well established in previous observational studies [14] . We were unable to demonstrate a relationship between markers of arterial stiffness and decline in renal function. These findings are in keeping with a prospective longitudinal analysis of the Framingham Offspring Study which did not find an association between baseline aortic PWV and incident CKD or microalbuminuria [37] . Three small studies have found an association. Taal et al [38] measured radial-dorsalis pedis PWV in 35 patients with Stage IV and V CKD and found PWV and AIx predicted progression to ESKD. Studying a cohort of patients with advanced CKD and the unorthodox use of radial-dorsalis pedis PWV rather than the gold standard carotid-femoral PWV may explain this difference. In a Japanese study of only 41 subjects with non-diabetic CKD, AIx predicted a greater decline in renal function [39] , although a subsequent study by this group of 42 patients failed to replicate this finding [40] . A third study of 133 patients with Stage III-IV CKD showed PWV predicted decline in renal function [24] . Although this study examined a similar patient cohort, a number of differences may collectively account for their contrasting findings: firstly, they used the Complior device, which generates higher aortic PWV measurements compared to the SphygmoCor [41] ; secondly, this group had poorer renal function with a mean eGFR of 32 compared to 43 mL/min/1.73 m 2 in our cohort; thirdly, although their subjects were treated to a target BP of 130/80 mmHg their actual achieved mean BP was 155/83 mmHg compared with 138/80 mmHg in our study, with a considerably higher pulse pressure potentially accounting for their higher reported PWV; fourthly, despite similar usage in the number of antihypertensives, our cohort had much greater use of agents targeting the renin-angiotensin-aldosterone axis which potentially have a greater influence on reducing arterial stiffness, particularly in CKD [2] ; fifthly, their patients were on average 11 years older than those in our study, and age is known to be a significant determinant of arterial stiffness [42] and finally, they had a higher proportion of diabetics compared to our study (23% versus 12%). Our study is larger than these three studies combined and has a much longer follow-up period. The differences between all of these studies including our own, however, highlight the fact that very little is known about the complex and presumably two way interactions between arterial stiffness and kidney disease. Research is hindered by the multiplicity of factors that influence this relationship in CKD patients including age, BP and medication [2] . The recent formation of collaborative networks such as EURECAM [43] and UREKA [44] will hopefully facilitate the recruitment of patients into much larger studies in order to address these important questions.
Our results raise the possibility that therapeutic lowering of phosphate levels might be an effective method of reducing the rate of decline of renal function. Similarly, our data support the control of systolic BP as a means of reducing progression of kidney dysfunction, although we have found no indication that lowering arterial stiffness would be associated with improved renal outcomes in this population.
Study limitations
There are potential limitations to our study. Although prospective, it is observational and cross-sectional in design and therefore subject to potential residual confounding from missing variables. We had only baseline measurements of arterial stiffness and were unable to longitudinally assess the relationship between changes in arterial stiffness and kidney disease. All subjects recruited into this study were under regular nephrologist's review and most had primary renal disease, potentially limiting applicability to patients with CKD treated solely in the community. Phosphate, however, is associated with cardiovascular morbidity and mortality in the general population as well as in CKD. We did not collect data on serum vitamin D or FGF-23 concentrations, which may have provided greater insight into potential aetiological mechanisms.
Conclusion
We have shown serum phosphate to be an independent predictor of decline in renal function in early stage chronic kidney disease. Further work is required to determine the underlying mechanisms through which phosphate influences kidney function decline and randomized controlled trials are warranted to investigate the benefits of phosphate lowering in the preservation of kidney function.
